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A B S T R A C T
Introduction: Diabetes mellitus (DM) is a leading driver of tuberculosis (TB) disease in TB-DM burdened coun-
tries. We aimed to assess the impact on TB disease of several intervention strategies targeting people with DM in
India.
Methods: A previously validated TB-DM mathematical model was extended to include interventions targeting
DM individuals. The model stratiﬁed the population by age, DM status, TB infection status and stage, TB disease
form, treatment, recovery, and intervention status.
Results: By 2050, diﬀerent TB vaccination strategies (coverage of 50 % and vaccine eﬃcacies ranging between
50 %–60 %) reduced TB incidence and mortality rates by 4.5 %–20.8 % and 4.1 %–22.1 %, respectively, and
averted 3.1 %–12.8 % of TB disease cases in the total population. Number of vaccinations needed to avert one TB
case (eﬀectiveness) was 14–105. Varying the coverage levels of latent TB treatment (coverage of 50 %–80 % and
drug eﬀectiveness of 90 %) reduced TB incidence and mortality rates by 7.1 %–11.3 % and 8.2 %–13.0 %,
respectively, averting 4.2 %–6.7 % of TB cases, with eﬀectiveness of 38–40. Diﬀerent scenarios for dual and
concurrent treatment of those with TB and DM, reduced TB incidence and mortality rates by 0.1 %–0.4 % and
1.3 %–4.8 %, respectively, averting 0.1 %–0.2 % of TB cases, with eﬀectiveness of 28–107. Diﬀerent scenarios
for managing and controlling DM (regardless of TB status) reduced TB incidence and mortality rates by 4.5
%–16.5 % and 6.5 %–22.2 %, respectively, averting 2.9 %–10.8 % of TB cases, with eﬀectiveness of 6–24.
Conclusion: Gains can be attained by targeting DM individuals with interventions to reduce TB burden. Most
strategies were eﬀective with<50 intervention doses needed to avert one TB disease case, informing key up-
dates of current treatment guidelines.
1. Introduction
Tuberculosis (TB) is a leading cause of mortality from infections
(World Health Organization, 2017a). In 2017, 10.0 million TB disease
incident cases and 1.3 million deaths were estimated globally (World
Health Organization, 2018a). TB incidence and mortality rates have
been declining globally, but slowly in most regions (e.g., incidence rate
has decreased by 1.9 % annually) (World Health Organization, 2018a).
Achieving the post-2015 End TB Strategy targets of reducing TB in-
cidence by 90 % and mortality by 95 %, by 2035 (WHO Tuberculosis
Programme, 2016), is therefore challenging and requires eﬀective im-
plementation of TB prevention in most aﬀected countries.
Many TB-burdened countries are also experiencing high and rising
diabetes mellitus (DM) burden, due to population ageing, nutrition
transition, and obesity (Hu, 2011; Santosa et al., 2014). People living
with DM have about 2–4 times higher risk of developing TB disease (Al-
Rifai et al., 2017), and experience poorer TB treatment outcomes
(Huangfu et al., 2019). Globally, 425 million people are living with DM,
a large proportion of them are undiagnosed, and possibly uncontrolled
(hemoglobin A1c (HbA1c)≥8.0 %), leading to an even greater risk for
TB disease and poorer TB treatment outcomes (Al-Rifai et al., 2017;
Critchley et al., 2018; Mahishale et al., 2017; Shewade et al., 2017).
With adult DM prevalence reaching 10 %–15 % by 2045 in parts of
Asia-Paciﬁc, DM could possibly oﬀset future declines in TB incidence
and mortality (Awad et al., 2019a, b), making it impossible to achieve
the TB goals. For example, 22 % of TB disease cases, and 30 % of TB-
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T
related deaths were estimated to be attributed to DM in India in 2017
(that is the burden of DM on TB) (Awad et al., 2019b), and by 2050, 33
% of TB disease cases and 43 % of TB-related deaths would be attrib-
uted to DM (Awad et al., 2019b).
At present, there is only one preventive (prophylactic) vaccine
against TB disease, the Bacillus Calmette-Guérin (BCG) vaccine (World
Health Organization, 2018a), which provides minimal protection of
uncertain duration (Abu-Raddad et al., 2009), but several vaccines are
being tested in clinical trials (Voss et al., 2018). Treatment of latent TB
infection (LTBI) is an eﬀective intervention against TB disease,
achieved by administering isoniazid or rifampin for 3–9 months (Kwon,
2017). Novel LTBI treatments are also being developed, potentially
with higher eﬃcacy, less side eﬀects, and simpler/shorter treatment
regimens (Kwon, 2017). With the promising availability of novel TB
interventions, assessments of the interventions’ impact on TB trans-
mission and disease burden is a priority, more so for the key at risk
populations, such as people with DM.
Current guidance from the World Health Organization (WHO) and
elsewhere recommends screening TB patients for DM and improving
DM control during TB treatment (Ekeke et al., 2017; Jali et al., 2013;
Lin et al., 2019a; Samal, 2016), though this is not routinely im-
plemented in low-middle income countries (International Union
Against Tuberculosis and Lung Disease and World Diabetes Foundation,
2015; Kapur et al., 2016). Beyond this guidance, there is little evidence
or consensus about how other interventions among DM individuals
might impact the TB epidemic (World Health Organization, 2018b). For
instance, with DM being a major contributor to TB disease (Ekeke et al.,
2017; Jali et al., 2013; Kapur et al., 2016; Samal, 2016), tackling the
pool of DM individuals latently infected with TB may be essential to
meeting the TB goals (Houben and Dodd, 2016).
We investigated the impact of intervention strategies for controlling
TB among people with DM in India using a previously validated TB-DM
mathematical model (Awad et al., 2019b), focusing on three main in-
tervention areas: 1) vaccination of DM individuals with novel TB vac-
cines, 2) treatment of LTBI among DM individuals latently infected with
TB, and 3) managing and controlling DM to alleviate the impact of DM
on TB (Table 1). These modelled interventions are described in detail
below.
2. Methods
2.1. Model structure
A recently-developed TB-DM age-structured deterministic model for
India was extended to include targeted interventions for people with
DM. Details of the original model are in previous studies (Awad et al.,
2019a, b). Brieﬂy, the dynamical model, capturing both the direct (e.g.,
DM increasing the risk of onset of TB disease) and indirect (e.g., onward
transmission of TB from people with and without DM) eﬀects of DM on
TB (Awad et al., 2019a, b), was described by a set of diﬀerential
equations stratifying the population according to age, TB infection and
disease status and form, TB treatment status, TB recovery status, and
DM status (Supplementary Material Text I-II). TB natural history and
treatment outcomes were assumed to be inﬂuenced by ten speciﬁc ef-
fects of having concurrent DM (Awad et al., 2019a) (Supplementary
Material Text I and Table S3). Accordingly, DM individuals followed a
distinct TB natural history from that of non-DM individuals (Figure S1)
(Awad et al., 2019a, b). The rate of DM onset in the model was assumed
to be both age (Gaussian function) and time (logistic function) depen-
dent, thus parameterized through a Gaussian-logistic function, and
ﬁtted to projections of the International Diabetes Federation for India
(International Diabetes Federation, 2017) (Supplementary Material
Text I, and Figure S2).
The population was further stratiﬁed by intervention status; all in-
terventions were targeted at people with DM. Interventions were in-
corporated into the model through a distinct and separate TB natural
history for the proportion of individuals undergoing the intervention
(Figure S1). Details of the extended model structure are in
Supplementary Material Text I.
The model was coded and analyzed in MATLAB R2018b (The
MathWorks and Inc. MATLAB, 2018).
2.2. Data sources and model ﬁtting
The model was parametrized using empirical evidence for TB nat-
ural history, and through model ﬁtting (Table S2 and Awad et al. (Awad
et al., 2019a, b)). The parametrization of the ten DM-on-TB eﬀects was
based on either pooling evidence from diﬀerent studies, or derived from
speciﬁc key observational studies (Table S3 and Awad et al. (Awad
et al., 2019b)). A conservative approach was opted whereby each DM-
on-TB eﬀect size was modest or set at the null value (i.e. DM has no
eﬀect on TB) if there was heterogeneity and uncertainty around the
exact eﬀect size or if evidence was not ﬁrmly established (Awad et al.,
2019a, b). The model was ﬁtted to TB incidence (Figure S3A) and
mortality (Figure S3B) rates (World Health Organization, 2017b), DM
prevalence (Figure S2A) (Anjana et al., 2017; International Diabetes
Federation, 2017), and demographics of India (Figure S3C) (United
Nations Department of Economic and Social Aﬀairs et al., 2017). TB
contact rate, case detection rate, age-speciﬁc DM onset rate, and age-
speciﬁc birth and death rates were derived by model ﬁtting. By ﬁtting
the case detection rate, the model thus implicitly aims to account for
the role of both the public and private sectors in diagnosing and
treating TB cases in India.
2.3. TB-DM interventions
For all modeled interventions, we assumed that the intervention was
initiated in 2020 and scaled up at a ﬁxed rate up to 2025. Intervention
coverage attained by 2025 was maintained throughout 2026-2050.
The primary modeled outcomes of interest were the proportional
reductions in TB incidence and TB mortality rates in the total population.
These measures were calculated by comparing the annual TB incidence
and mortality rates in the intervention scenario, with that of the
baseline scenario of no intervention. The proportion of TB disease cases
that are averted by the intervention (between 2020–2050) was also
calculated by comparing the intervention and the baseline scenario.
Population-level eﬀectiveness of the TB-DM intervention was deﬁned as
the number of individuals required to undergo the intervention to avert
one TB disease case (that is the “number needed to treat” (The Centre
for Evidence-Based Medicine, 2019)), and was estimated by dividing
the number of DM cases required to undergo the intervention, by the
number of TB disease cases averted, over the chosen time horizon.
2.4. Intervention program scenarios
2.4.1. TB vaccination
Two diﬀerent types of TB vaccines were modelled: pre-exposure
(prophylactic) and post-exposure vaccines, to reﬂect current vaccine
pipeline under development (Voss et al., 2018). The pre-exposure
vaccine was administered to DM individuals who are uninfected but
susceptible to TB. The post-exposure vaccine was administered to DM
individuals who are latently TB infected. For both vaccines, vaccine
immunity was assumed to wane with time.
The “eﬃcacy” of the vaccine was deﬁned (per convention) as the
proportional reduction in the risk of TB infection and/or disease and/or
transmission among vaccinated individuals, as would be measured in
randomized clinical trials. The pre-exposure vaccine was assumed to
reduce the fraction of TB infected persons who were TB fast progressors,
by a fraction VEP. Both pre-exposure and post-exposure vaccines were
assumed to reduce the infectiousness of those vaccinated who became
infected and developed TB disease, by a fraction VEI . Also, both vac-
cines were assumed to reduce the progression rate to TB disease for
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3
those latently infected (that is TB slow progressors), by a fraction
VEPVLS. These assumptions were based on existing assumptions for the
biological eﬀects of these vaccines (Abu-Raddad et al., 2009). The
modelled vaccine scenarios along with their parametrization of cov-
erage, eﬃcacies, and protection duration are summarized in Table 1.
In a sensitivity analysis of a combination scenario of both post- and
pre-exposure vaccines, we assessed the impact of diﬀerent vaccination
coverage levels ranging from 0 %–90 %, vaccine eﬃcacies varying
(individually) from 0 %–100 %, and vaccine immunity duration from
one year to lifelong.
In a second sensitivity analysis of a combination scenario of both post-
and pre-exposure vaccines, and in context of uncertainty about the fu-
ture DM prevalence trajectory over the coming decades, we assessed the
impact of vaccination assuming diﬀerent DM prevalence
trajectories—DM prevalence was assumed to be reduced by 40 %
reaching 5 % by 2050, or to remain constant at 8 % between 2020 and
2050, in addition to our baseline model of growing prevalence per the
projections of the International Diabetes Federation (International
Diabetes Federation, 2017) (Figure S2).
Additional sensitivity analyses were conducted to assess the sensi-
tivity of model predictions to variations in TB epidemiological and
natural history parameters (Table S2), and to variations in the eﬀect
sizes of the DM-on-TB eﬀects (Table S3). For each individual parameter,
we either used the lower and upper values from either the CI or as-
sumed±25 % uncertainty around the point estimates if the un-
certainty was not captured by a CI. For instance, for Eﬀect 1-
Susceptibility, a range of 1.0–2.2 was used based on the reported 95 % CI
for that eﬀect (Martinez et al., 2017); for Eﬀect 2-Fast progression, a
range of 1.3–1.8 was used based on the reported 95 % CI of the pooled
TB-DM association (Al-Rifai et al., 2017); and for Eﬀect 6-Disease in-
fectiousness, a range of± 25 % around the point estimate was used (i.e.
1.1–1.8; Table S3).
2.4.2. Treatment of latent TB as preventive therapy
LTBI treatment was modelled to be administered to DM individuals
latently infected with TB to reach i) 50 % and ii) 80 % treatment
coverage by 2025. The treatment was assumed to prevent progression
to TB disease with a drug eﬃcacy of 90 % (Table 1). Individuals suc-
cessfully treated move to the recovery state, but can in principle be
reinfected subsequently with TB.
At present, there are no national or international recommendations
to treat DM patients with LTBI. However, if such recommendations
were introduced in the future, clinical and laboratory examinations to
rule out active TB disease would need to be carried out according to
national policies before any decision to initiate LTBI treatment as a
preventive therapy (World Health Organization, 2018c). People living
with DM would thus require screening for active TB disease before any
screening and treatment for LTBI. An additional analysis was therefore
carried out assuming that those people with active TB disease were
identiﬁed and treated ﬁrst. This was done by assuming screening and
treatment for TB disease and LTBI treatment would be administered at
the same annual rate to individuals with DM who had either active TB
Fig. 1. Projected outcomes of the impact of tuberculosis (TB) vaccination targeting individuals with diabetes mellitus (DM). A) Reduction in TB disease incidence
rate. B) Reduction in TB mortality rate. C) Proportion of averted TB disease incident cases. D) Number of vaccinations needed to avert one TB disease case
(eﬀectiveness) by 2025, 2030, 2040, and 2050. Vaccine coverage was scaled-up to 50 % by 2025 and then maintained at this level thereafter.
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disease or LTBI. Overall treatment coverage (for active TB disease or
LTBI) reached 50 % for DM patients by 2025.
A sensitivity analysis was conducted to assess whether the impact of
LTBI treatment could have been underestimated, by assuming that DM
increases progression to TB disease not only for TB primary infection,
but also for TB reactivation, given biological plausibility (Awad et al.,
2019a, b) (Supplementary Material Text III). Coverage of LTBI treat-
ment was set here at 50 % by 2025.
2.4.3. Controlling DM for improved TB progression and treatment outcomes
Several modelled intervention scenarios assessed the impact on TB
of managing and controlling DM (i.e. HbA1c level< 8 % (American
Diabetes Association, 2017)). As supported by existing evidence (Al-
Rifai et al., 2017; Critchley et al., 2018; Mahishale et al., 2017;
Shewade et al., 2017), controlling DM was assumed to reduce the DM-
on-TB eﬀects relative to those with uncontrolled DM (Table 1).
2.5. Patient and public involvement
Neither patients nor the public were involved in the study.
3. Results
In the no-intervention (baseline) scenario, TB disease incidence and
mortality rates in India (per 100,000 population per year) were pro-
jected to decline from 190.1 and 36.9 in 2018, to 177.0 and 34.0 by
2020 (Figure S3A), and to 102.3 and 18.1 by 2050 (Figure S3B), re-
spectively. Cumulative number of new TB cases between 2020–2050
was projected at 55.2 million.
3.1. TB vaccination
Fig. 1 shows the impact of TB vaccination targeting people with DM
on TB disease, while Figure S4A shows the projected TB incidence rate
given the diﬀerent TB vaccination strategies. By 2050, the reduction in
TB incidence rate ranged from 4.5 % (post-exposure vaccine scenario)
to 20.8 % (combination scenario of pre- and post-exposure vaccination;
Fig. 1A and Figure S4). Here, the reduction in TB mortality rate ranged
from 4.1 %–22.1 %, respectively (Fig. 1B). By 2050, 3.1 %–12.8 % of TB
disease cases were averted by the scenarios, that is a total of 1.7–7.1
million cases (Fig. 1C).
By 2025, vaccination eﬀectiveness ranged from 90 (optimistic pre-
exposure vaccine scenario) to 346 (post-exposure vaccine scenario);
Fig. 2. Projected outcomes of the impact of latent tuberculosis (TB) treatment as a preventive therapy targeting individuals with diabetes mellitus (DM). A)
Reduction in TB disease incidence rate. B) Reduction in TB mortality rate. C) Proportion of averted TB disease incident cases. D) Number of vaccinations needed to
avert one TB disease case (eﬀectiveness) by 2025, 2030, 2040, and 2050. Treatment coverage was scaled-up to the indicated level by 2025, and then maintained at this
level thereafter.
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and by 2050, eﬀectiveness ranged from 14 to 105 (Fig. 1D). The impact
of the combination of pre-and post-exposure vaccination was larger
than that of the individual pre- and post-exposure vaccinations, but the
eﬀectiveness was inferior, as more vaccinations were needed to avert
one TB disease case.
The robustness of our results was assessed in a series of sensitivity
analyses (Figure S5). Altering vaccine coverage from 10 %–90 %, re-
duced TB incidence rate by 4.0 %–34.4 % by 2050, while eﬀectiveness
stayed constant at 17. TB incidence rate was reduced by 15.6 %–23.4
%, 17.2 %–23.6 %, and 19.3 %–21.1 % as each of the vaccine eﬃcacies
of VEP, VEI , and VEPVLS, respectively, varied independently (and not
simultaneously) from 0 %–100 %. Vaccine eﬀectiveness ranged from 15
to 23, 15 to 20, and 17 to18, as each of the vaccine eﬃcacies of VEP,
VEI , and VEPVLS, respectively, varied independently from 100 % down to
0 %. Increasing vaccine immunity from 1 year to lifelong protection,
reduced TB incidence rate by 2.8 %–20.8 %, with vaccine eﬀectiveness
ranging from 17 to 157.
In further sensitivity analyses, the impact of TB vaccination on TB
incidence and mortality was altered by diﬀerent DM prevalence tra-
jectories (Figure S6). In 2050, the reduction in TB incidence rate ranged
between 11.6 % (declining DM prevalence scenario) and 20.8 %
(growing DM prevalence as per the projections of the International
Diabetes Federation (International Diabetes Federation, 2017) (Figure
S6A). Meanwhile, the reduction in TB mortality rate ranged from 12.8
%–22.1 % (Figure S6B). However, vaccine eﬀectiveness remained es-
sentially the same regardless of the future trajectory of DM prevalence
(Figure S6C).
3.2. Treatment of latent TB as preventive therapy
Fig. 2 shows the impact of LTBI treatment targeting people with
DM, while Figure S4B shows the projected TB incidence rate of the
diﬀerent LTBI treatment strategies. By 2050, the reduction in TB in-
cidence rate was 7.1 % for the 50 % and 11.3 % for the 80 % LTBI-
treatment coverage scenarios, respectively (Fig. 2A and Figure S4B).
Here, the reduction in TB mortality rate was 8.2 % and 13.0 %, re-
spectively (Fig. 2B). By 2050, 4.2 %–6.7 % of TB disease cases were
averted, that is a total of 2.3–3.7 million cases (Fig. 2C).
By 2025, eﬀectiveness of LTBI treatment was 278 for the 80 % and
322 for the 50 % coverage scenarios, respectively; and by 2050, ef-
fectiveness was 38 and 40, respectively (Fig. 2D).
By reaching an overall treatment coverage of 50 % among DM in-
dividuals with active TB disease or latent TB infection, the reduction in
TB incidence rate was 8.9 % (Figre 2A), the reduction in TB mortality
rate was 10.7 % (Figure 2B), 5.7 % of TB disease cases were averted
(Fig. 2C), and the eﬀectiveness of treatment was 29 (Fig. 2D), all by
2050. About two percentage points of the impact on TB incidence rate
were due to the screening and treatment of TB disease, while the re-
maining seven percentage points of the impact were due to LTBI
treatment.
In the sensitivity analysis assuming that DM increases progression to
TB disease also for TB reactivation, eﬀectiveness of LTBI treatment was
superior to the above scenarios—for example, by 2050, LTBI-treatment
eﬀectiveness was only 27 (Fig. 2D).
3.3. Managing and controlling DM for improved TB progression and
treatment outcomes
Fig. 3 shows the impact of reducing the eﬀects of DM on TB treat-
ment outcomes by dually and concurrently treating those with TB dis-
ease and DM. By 2050, with coverage of eﬀective DM management (i.e.
reducing the eﬀects of DM on TB) ranging from 20 % to 100%, the
reduction in TB incidence rate ranged from 0.1 %–0.4 % (Fig. 3A and
Figure S4B), and the reduction in TB mortality rate ranged from 1.3
%–4.8 % (Fig. 3B). By 2050, 0.1 %–0.2 % of TB disease cases were
averted, that is a total of 28,803–108,893 cases (Fig. 3C).
By 2025, eﬀectiveness of dual and concurrent TB-DM treatment
ranged from 147 to 573 with coverage of DM management ranging
from 100 % down to 20 %; and by 2050, eﬀectiveness ranged from 28
to 107 (Fig. 3D).
Fig. 4 shows the impact of improved management and control of DM
in people with DM regardless of their TB status and stage. By 2050, with
DM-management coverage ranging from 20 % to 100%, the reduction
in TB incidence rate ranged from 4.5 %–16.5 % (Fig. 4A and Figure
S4B), and the reduction in TB mortality rate ranged from 6.5 %–22.2 %
(Fig. 4B). By 2050, 2.9 %–10.8 % of TB disease cases were averted, that
is a total of 1.6–5.9 million cases (Fig. 4C).
By 2025, eﬀectiveness of improved DM management and control
ranged from 29 to 121 with DM-management coverage ranging from
100 % down to 20 %; and by 2050, eﬀectiveness ranged from 6 to 24
(Fig. 4D).
4. Discussion
Using an analytical approach, we quantitatively assessed the impact
of interventions targeting people living with DM to reduce TB incidence
and mortality in India, the country most aﬀected by the dual TB-DM
epidemic (Awad et al., 2019b). We found that substantial reductions in
TB incidence and mortality could be achieved through TB vaccination,
LTBI treatment, and managing and controlling DM. Administering TB
vaccination to DM individuals (before being exposed to TB), or mana-
ging and controlling DM in those living with DM, was most impactful in
reducing TB incidence and mortality rates by up to 22 %. LTBI treat-
ment targeting the reservoir of DM individuals who are already TB la-
tently infected had also important public health beneﬁts reducing TB
incidence and mortality rates by up to 13 %. While these interventions
do not solely achieve the post-2015 End TB targets (Figure S4), each
oﬀers substantial reductions in TB burden making the targets more
manageable.
In context of strong eﬀects for DM on TB natural history, treatment
outcomes, and epidemiology (Al-Rifai et al., 2017; Awad et al., 2019a,
b; Huangfu et al., 2019), these ﬁndings highlight how interventions
targeting people with DM should be at the core of the post-2015 End TB
Strategy, and are integral to achieving this strategy’s targets of reducing
TB incidence by 90 % and mortality by 95 %, by 2035 (WHO
Tuberculosis Programme, 2016). While our study was on India, this
approach can be generalised to other TB-DM burdened countries, with
probably similar beneﬁcial impact.
Diﬀerent vaccine scenarios, informed by current TB vaccine devel-
opment (Voss et al., 2018), were found to reduce TB incidence by 5
%–21 % and mortality by 4 %–22 % (Fig. 1). In the optimistic combi-
nation vaccine scenario (of both post- and pre-exposure vaccination),
about half of the burden (i.e. negative eﬀects) of DM on TB could be
mitigated (Fig. 1C). However, the public health beneﬁts of TB vacci-
nation were strongly dependent on the type (pre-exposure versus post-
exposure vaccine), eﬃcacy, coverage level, and importantly, duration
of protection that the vaccine would entail (Figs. 1 and S2). Eﬀective-
ness of a pre-exposure vaccine was superior to that of a post-exposure
vaccine—only 14 (versus 105) pre-exposure vaccinations were needed
to avert one TB disease case by 2050 (Fig. 1D). Though the impact of a
post-exposure vaccine was inferior, it was immediately realized, as it
aﬀected those who are already (latently) TB infected (Fig. 1). The
longer the duration of vaccine protection, the better was eﬀective-
ness—131 vaccinations were needed to avert one TB disease case by
2050 for a vaccine immunity lasting ﬁve years, versus 17 for lifelong
immunity (Figure S2).
LTBI treatment at high coverage of 80 % reduced TB incidence by
11 %, mortality by 13 %, and averted 7 % of TB disease cases (Fig. 2).
The impact of LTBI treatment was also immediately realized (Fig. 2).
However, LTBI treatment at 80 % coverage was only half as impactful
as the combination vaccine scenario, since LTBI treatment aﬀects only
those latently infected, while the combination vaccine aﬀects people
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before and after TB infection (Fig. 2 versus Fig. 1). Meanwhile, the
impact of LTBI treatment was twice as large as that of a post-exposure
vaccine (also targeting those latently infected), as LTBI treatment has
higher eﬃcacy (90 %) than that assumed for a post-exposure vaccine
(50 %) (Fig. 2 versus Fig. 1).
Most recent joint TB-DM management guidelines do not strongly
promote screening DM patients for active TB disease (Lin et al., 2019b),
mainly because several studies have identiﬁed few or no cases of active
TB disease, and have also identiﬁed many practical diﬃculties with
access to TB screening or diagnostic facilities (Kumpatla et al., 2013;
Mtwangambate et al., 2014; Prakash et al., 2013). However, screening
for active TB disease as part of a strategy to screen and treat LTBI could
be more eﬀective, due to the substantially higher yield that would be
expected. When screening and treatment for active TB disease was in-
cluded in the LTBI treatment scenario (Fig. 2), the impact of the in-
tervention was realized faster than the scenario with only LTBI treat-
ment. Still, in this scenario the impact of such intervention was mostly
arising from the treatment of the latently infected rather than the
screening and treatment of active disease (Fig. 2). This is mainly due to
the fact that the number of DM-active TB disease cases treated in this
scenario was meagre compared to the number of DM-latently infected
cases that are treated.
These ﬁndings come at a critical time as the WHO was recently
unable to formulate any clear guidance about treating LTBI in people
with DM (World Health Organization, 2018b). Guidelines by the United
States Preventive Services Task Force do not also currently recommend
screening and treatment of LTBI in people with DM, indicating that
there is not yet suﬃcient evidence to recommend such treatment
(Bibbins-Domingo et al., 2016). Our results inform these deliberations
by providing concrete quantiﬁcation of the potential population-level
impact of this intervention, and indicate that LTBI treatment should be
integral to these guidelines, as it is an eﬀective intervention that uses
generic low-cost drugs and alleviates diﬀerent negative eﬀects of DM on
TB natural history and treatment outcomes.
While dual and concurrent treatment of TB and DM has an im-
portant impact at the individual-level, the population-level impact was
limited (Fig. 3). This intervention aﬀects only a small proportion of the
population, those with concurrent DM and TB disease, and is im-
plemented well after DM has had its toll on TB natural history for a
given aﬀected person. This intervention also primarily impacts TB
mortality, rather TB disease incidence (Fig. 3). Despite the limited po-
pulation-level impact, the eﬀectiveness is of value (Fig. 3D)—a small
number of treatments is needed to avert one TB disease case (∼50).
These ﬁndings reinforce current guidelines that recommend screening
of TB patients for DM, and improving DM control during TB treatment
(Ekeke et al., 2017; Jali et al., 2013; Lin et al., 2019a; Samal, 2016).
However, they also demonstrate that the excessive focus of TB-DM
control on screening for and managing DM among TB patients will not
have much signiﬁcant population-level impact on the TB-DM epi-
demics.
Our results demonstrate that managing and controlling DM is po-
tentially a powerful intervention that can reduce TB disease by up to 17
Fig. 3. Projected outcomes of the impact of dual and concurrent treatment of tuberculosis (TB) disease and diabetes mellitus (DM). A) Reduction in TB disease
incidence rate. B) Reduction in TB mortality rate. C) Proportion of averted TB disease incident cases. D) Number of vaccinations needed to avert one TB disease case
(eﬀectiveness) by 2025, 2030, 2040, and 2050. Dual TB-DM treatment coverage was scaled-up to 50 % by 2025, and then maintained at this level thereafter.
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% and mortality by up to 22 % (Fig. 4). Improved DM management has
also superior eﬀectiveness compared to all other studied interventions
(Fig. 4D), as only about ten people with DM require better management
to avert one TB disease case. The impact of improved DM management
is also immediately realized, with most gains rapidly materializing in
comparison to vaccination whose impact takes time to materialize
(Fig. 4 versus Fig. 1). These ﬁndings demonstrate the potential popu-
lation importance for TB epidemics of strengthening DM services and
management in India and other countries enduring large double TB-DM
burden. Improved DM management would also have multiple other
positive consequences, beyond reducing TB incidence and mortality,
such as reducing the risk of other DM complications and cardiovascular
disease. To date though, a large proportion of DM cases in India remain
undiagnosed, and probably with uncontrolled DM (International
Diabetes Federation, 2017).
This study has limitations. Eﬀect sizes of several of the DM-on-TB
eﬀects are not yet known with precision (Awad et al., 2019a, b), and
this uncertainty may aﬀect the assessed intervention impact. We as-
sumed speciﬁc or a range of eﬃcacies for some of the interventions,
such as for the vaccines, but the exact eﬃcacies will not be known until
ﬁnal development of the intervention product. Future projections of TB
incidence rate are intrinsically uncertain and subject to unknown fac-
tors, such as future scale-up of other TB interventions, but this may
aﬀect the assessed impact. At present, we do not have speciﬁc inter-
ventions (e.g. TB vaccines, LTBI treatment regiments, improved dia-
betes management) that have been shown in randomised trials to
reduce the risk of TB disease among people living with DM. Hence, our
analyses are best viewed as demonstrating the potential of such inter-
ventions rather than as precise estimates of their likely range of eﬀects.
Despite these limitations, the model has key strengths such as inclusion
of several diﬀerent eﬀects through which DM can aﬀect TB natural
history and treatment outcomes, incorporation of the age-speciﬁc
trends, and assessing both the direct and indirect population impacts of
DM on TB. It is also possible that we may have underestimated (rather
than overestimated) the impact of the interventions, as the impact of
DM on TB is probably underestimated (Awad et al., 2019b).
We assumed speciﬁc input parameter values (Tables S2 and S3) and
did not explore the impact on the predictions of variability in these
parameters through an uncertainty analysis, since the interventions are
largely hypothetical at present. However, we conducted several sensi-
tivity analyses to explore the potential impact of many of these para-
meters. The sensitivity analyses demonstrated that the results were
most sensitive to Eﬀect 6-Disease infectiousness, Eﬀect 1-Susceptibility,
and Eﬀect 2-Fast progression (Figure S7), given the impact of these ef-
fects on TB epidemiology (Awad et al., 2019b). Explicitly, with an eﬀect
size for Eﬀect 6-Disease infectiousness ranging between 1.1–1.8, vaccine
eﬀectiveness ranged between 13.7–22.5; with an eﬀect size for Eﬀect 1-
Susceptibility ranging between 1.0–2.2, vaccine eﬀectiveness ranged
between 14.3–20.8; and with an eﬀect size for Eﬀect 2-Fast progression
ranging between 1.3–1.8, vaccine eﬀectiveness ranged between
15.1–21.1 (Figure S7). Otherwise, our results were largely insensitive to
variations in the rest of the explored eﬀects (Figure S7). Our results
Fig. 4. Projected outcomes of the impact of managing and controlling diabetes mellitus (DM) in DM individuals regardless of tuberculosis (TB) status. A) Reduction in
TB disease incidence rate. B) Reduction in TB mortality rate. C) Proportion of averted TB disease incident cases. D) Number of vaccinations needed to avert one TB
disease case (eﬀectiveness) by 2025, 2030, 2040, and 2050. DM management coverage was scaled-up to 50 % by 2025, and then maintained at this level thereafter.
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were also insensitive to variations in the TB epidemiological and nat-
ural history parameters (Figure S8).
In conclusion, there are major gains to be attained by targeting
people with DM with interventions to reduce TB incidence and mor-
tality. Most interventions were eﬀective with< 50 intervention doses
needed to avert one TB disease case. While none of the interventions
could mitigate completely the adverse burden of DM on TB, several,
such as TB vaccination and controlling and managing DM, can reduce
this burden by as much as half. These ﬁndings demonstrate the urgency
of continuing development of novel interventions targeting the dual TB-
DM epidemic, and aﬃrm the relevance of the concept of “know your
epidemic, know your response” for tackling TB (WHO Tuberculosis
Programme, 2016), as a critical and indispensable approach to ad-
dressing TB disease burden. The ﬁndings also highlight the relevance of
joint TB-DM healthcare services, such as integrating better DM man-
agement and control services, which is vital to managing TB epidemics
in places like India.
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